Handbook of Clinical medicine

end-points which do not directly measure benefi t, harm, or the treatment response of interest. • How long was the follow-up? Was it long enough to determine outcome? • How complete was the follow-up? How many patients were left at the end of the follow-up period? Were those who left the study included in the analysis (intention-to-treat)?25 When a randomized controlled trial might not be the best method • Generating new ideas beyond current paradigms (case reports). • Researching causes of illnesses and prognoses (cohort studies). • Evaluating diagnostic tests (cohort study and decision model). • Where the researcher has no idea of the eff ective dose of a drug (dose-ranging adaptive design). • When recruiting of patients would be impossible or unethical. • When personalized medicine is the aim, eg treatments matched to patients’ bio- marker profi les (adaptive design, cohort study). In the end, all randomized trials have to submit to the ultimate test when the sta- tistical collides with the personal: ‘Will this treatment help me?’, ‘Will this procedure help you?’ No randomized trial is complete until real-life decisions taken in the light of its fi ndings are scrutinized. Remember Osler: ‘no two individuals react alike and
